[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363480-105":59,"doc-detail-363480-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","deruxtecan-based-antibodydrug-conjugates-induce-senescence-in-her2-positive-breast-cancer","Deruxtecan-based antibody–drug conjugates induce senescence in HER2-positive breast cancer","","Breast cancer remains a leading cause of cancer-related death in women, and resistance—de novo or acquired—continues to hinder therapy. Antibody–drug conjugates have expanded treatment options, with trastuzumab-deruxtecan (T-DXd) showing improved efficacy in advanced or metastatic HER2-positive disease. The study identifies resistance mechanisms including reduced payload target (Topoisomerase I) and sustained senescence, linked to increased reactive oxygen species, metabolic rewiring, p53/p21 activation, and SASP, with DXd-driven induction confirmed using additional DXd-based ADCs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deruxtecan-based-antibodydrug-conjugates-induce-senescence-in-her2-positive-breast-cancer/363480/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deruxtecan-based-antibodydrug-conjugates-induce-senescence-in-her2-positive-breast-cancer/363480.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What resistance mechanisms are identified for HER2-positive breast cancer treated with deruxtecan-based ADCs?","Question",{"text":112,"@type":113},"The document identifies two mechanisms: reduction of the payload target (Topoisomerase I) and induction of sustained senescence. The phenotype is associated with increased reactive oxygen species, metabolic rewiring, and activation of the p53/p21 axis, together with SASP.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study determine whether the antibody or the payload drives senescence?",{"text":117,"@type":113},"It dissects the relative contribution of trastuzumab (the antibody) versus DXd (the payload). The findings show that DXd alone is sufficient to promote senescence and downstream effects.",{"name":119,"@type":110,"acceptedAnswer":120},"Which additional ADC evidence supports the conclusions about DXd-based drugs?",{"text":121,"@type":113},"The study corroborates results using another DXd-based ADC, Datopotamab-DXd, and reports that DXd-based drugs promote Topoisomerase I downregulation and senescence.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363480,1790684758,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDeruxtecan-based antibody–drugconjugates induce senescence in HER2-positive breast cancer  \nElena Vezzoli1,11, Riccardo Pinos2,11, Silvia Galbiati3, Desiree Zambroni1, Chiara Dall’Ara4,9,  \nAlberta Locatelli4, Emanuele Colombo1, Barbara Galbardi4, Lucia Viganò4, Zeno Lavagnino5,10, Cristina Scielzo2,6, Clara De Palma7, Giampaolo Bianchini4,6, Carlo Tacchetti6,8 & Tiziana Daniele8,12􀀍  \nBreast cancer (BrCa) represents one of the most common malignancies and the leading cause of cancerrelated deaths in women worldwide. Despite the advances in therapeutic treatments, de novo and/ or acquired resistance still represents a major clinical challenge. Recently, a new class of therapeutic agents has been approved for the treatment of advanced/metastatic BrCa: antibody–drug conjugates (ADCs). Trastuzumab-deruxtecan (T-DXd) has recently become the prevalent treatment in different clinical settings because of its improved efficacy. Here, we identified two mechanisms of resistance:  \ni. reduction of the payload target (Topoisomerase I) and ii. induction of sustained senescence. This phenotype correlates with increased production of reactive oxygen species (ROS), metabolic rewiring and activation of the p53/p21 axis, and is associated to the senescence-associated secretory phenotype (SASP). Furthermore, dissection of the relative contribution of the antibody (Trastuzumab) vs the payload (DXd) component oftheADCtothe action ofT-DXd showed that DXd alone is sufficient to promote senescence and its downstream effects. We further corroborated these conclusions exploiting another DXd-based ADC (Datopotamab-DXd) and found that DXd-based drugs promote Topoisomerase I downregulation and senescence. Altogether, these findings provide the rationale for the treatment of breast cancer patients resistant to DXd-based ADCswith senolytic or senomorphic agents.  \nKeywords HER2, Breast cancer, Trastuzumab, Trastuzumab-deruxtecan, Deruxtecan, Datopotamabderuxtecan, Senescence, SASP, 3D bioprinting, Mitochondria  \nBreast cancer (BrCa) represents one of the most common malignancies and the leading cause of cancer-related deaths in women worldwide. Despite the advances in therapeutic treatments, de novo and/or acquired resistance still represents a major clinical challenge. Different subtypes of BrCa have been classified based on the expression of specific markers, namely estrogen receptor (ER)-positive, progesterone positive (PgR)-positive, Epidermal Growth Factor Receptor type 2 (HER2 or ErbB2)-positive and triple-negative (TNBC) . Approximately 15% of BrCa display HER2 gene amplification or protein overexpression and show high risk of relapse and shorter survival1. Standard of care for HER2-positive patients comprise a combination of chemotherapy and targeted humanized monoclonal antibodies (Trastuzumab and Pertuzumab), administered in either neoadjuvant oradjuvant setting, regardless of the levels of expression of estrogen and progesterone receptors in the tumour.  \n1Advanced Light and Electron Microscopy Bioimaging Center ALEMBIC, Experimental Imaging Centre, IRCCSSan Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. 2Malignant B Cells Biology and 3D Modelling Unit, Experimental Oncology Division, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. 3Complication of Diabetes Unit, Diabetes Research Institute, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy.  \n4Medical Oncology Department, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. 5Imaging of Gene Regulation Unit, Experimental Imaging Centre, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy.  \n6Vita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy. 7Department of Medical Biotechnology and Translational Medicine (BioMeTra), Università Degli Studi Di Milano, Segrate, Italy. 8Cancer Imaging Unit, Experimental Imaging Centre, IRCCS S","cbCaipgqMQyuCPjO","https://ap.wps.com/l/cbCaipgqMQyuCPjO","pdf",4748758,18,"English","# Background\n# Resistance mechanisms and senescence phenotype\n# Role of antibody versus payload\n# Further validation with additional DXd-based ADCs\n# Therapeutic rationale for resistant breast cancer","[{\"question\":\"What resistance mechanisms are identified for HER2-positive breast cancer treated with deruxtecan-based ADCs?\",\"answer\":\"The document identifies two mechanisms: reduction of the payload target (Topoisomerase I) and induction of sustained senescence. The phenotype is associated with increased reactive oxygen species, metabolic rewiring, and activation of the p53/p21 axis, together with SASP.\"},{\"question\":\"How does the study determine whether the antibody or the payload drives senescence?\",\"answer\":\"It dissects the relative contribution of trastuzumab (the antibody) versus DXd (the payload). The findings show that DXd alone is sufficient to promote senescence and downstream effects.\"},{\"question\":\"Which additional ADC evidence supports the conclusions about DXd-based drugs?\",\"answer\":\"The study corroborates results using another DXd-based ADC, Datopotamab-DXd, and reports that DXd-based drugs promote Topoisomerase I downregulation and senescence.\"}]","Deruxtecan-based antibody–drug conjugates induce senescence in HER2-positive breast cancer | PDF",1790151421,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92c4460bbc913083181cb5cf2c9ab47e.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/726c2e3979d1da2fccd72883aad747b7.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbe85ea5959e8651222f6a6229975c05.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/179f8822bc7a9d36136bc9db3e93bb30.webp",980,1287]